Q-Line Biotech Ltd has outlined an ambitious growth plan for FY27, targeting revenue growth of 30-35 percent through export expansion, contract manufacturing and new product launches.
The company detailed its strategy in an investor presentation released through a Regulation 30 filing with the National Stock Exchange ahead of an analyst and institutional investor call.
With a market capitalisation of ₹1,388.03 crore, the stock was trading at ₹595, up 2.28 percent from the previous close of ₹581.75. The shares are about 0.8 percent below their 52-week high of ₹600.
Export push
Q-Line Biotech has appointed a Dubai-based international business manager and signed distributor agreements in seven to eight countries.
Export revenue stood at ₹1.18 crore in FY26.
Management expects exports to increase about fivefold in FY27.
Target markets include:
- African Union countries
- Middle East
- Indian subcontinent
Focus on contract manufacturing
The company is expanding into the contract development and manufacturing (CDMO) business.
Plans include manufacturing:
- Selectra Pro M
- Microlab 300
These instruments will be produced under an exclusive technical collaboration for export markets.
Management said it has already:
- Reduced costs for three CDMO clients.
- Sourced end-of-life components for those customers.
No revenue guidance has been provided for the CDMO business.
Capacity expansion
Unit 4, commissioned in February 2026, has secured licences for five products.
The company expects commercial production of clinical chemistry reagents to begin in the second quarter of FY27, subject to regulatory approvals.
Product launches
Q-Line Biotech plans to launch the Microlab 300 semi-automatic analyser during Q2 FY27.
Other products under development include:
- A haematology analyser.
- A coagulation analyser being developed with Stago.
Process improvements
The company is also investing in internal systems.
Initiatives include:
- Completion of an ERP rollout by the end of FY27.
- Engagement with PwC to strengthen financial controls and governance.
FY27 target follows slower FY26 growth
Q-Line Biotech reported revenue growth of 9 percent in FY26.
Segment performance varied sharply.
- Reagents, which account for nearly 70 percent of revenue, grew 35 percent.
- Diagnostic instruments revenue declined by about 25 percent.
- Services revenue nearly halved.
Management is also attempting to reduce geographical concentration.
Currently, 77-84 percent of revenue comes from northern India, with Uttar Pradesh contributing the largest share.
Expansion plans cover:
- Southern India
- Eastern India
- Western India
- International markets
FY26 performance
For FY26:
- Revenue increased to ₹341.74 crore, up 9 percent year-on-year.
- EBITDA rose 39 percent to ₹98.05 crore.
- EBITDA margin improved from 22.5 percent to 28.7 percent.
- Net profit climbed 190 percent to ₹55.72 crore.
- Profit before tax increased 28 percent.
The company also reported:
- Debtor days rising from 69.9 days to 96.2 days.
- Higher borrowings during the year.
About the company
Formerly known as POCT Services Private Limited, Q-Line Biotech Ltd develops and manufactures diagnostic reagents, instruments and consumables for the in-vitro diagnostics market.
Its products are supplied to:
- Laboratories
- Hospitals
- Medical colleges
The company operates four manufacturing units in Lucknow and Delhi and serves customers across 26 states.
Q-Line Biotech was listed on the NSE SME platform on May 29, 2026, raising ₹214.48 crore through a fresh issue.
Promoters hold around 68 percent of the company after the listing.
TL;DR:
Q-Line Biotech is targeting 30-35% revenue growth in FY27 through exports, contract manufacturing and new product launches. The diagnostics company reported 9% revenue growth in FY26 and recently commissioned a new manufacturing unit.
AI summary:
- Q-Line Biotech aims for 30-35% revenue growth in FY27.
- The company plans to expand exports and enter the CDMO segment.
- Unit 4 is expected to begin reagent production in Q2 FY27.
- The Microlab 300 analyser is scheduled for launch in Q2 FY27.
- FY26 revenue rose 9% to ₹341.74 crore.
Disclaimer : Opinions and investment insights shared by experts are personal and independent. Management assume no responsibility for investment decisions made based on such views. Investors should seek guidance from qualified financial professionals prior to acting.
